Sheldon L. Holder

1.4k total citations · 1 hit paper
40 papers, 1.0k citations indexed

About

Sheldon L. Holder is a scholar working on Surgery, Oncology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Sheldon L. Holder has authored 40 papers receiving a total of 1.0k indexed citations (citations by other indexed papers that have themselves been cited), including 22 papers in Surgery, 15 papers in Oncology and 14 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Sheldon L. Holder's work include Bladder and Urothelial Cancer Treatments (21 papers), Urinary and Genital Oncology Studies (12 papers) and Cancer Mechanisms and Therapy (10 papers). Sheldon L. Holder is often cited by papers focused on Bladder and Urothelial Cancer Treatments (21 papers), Urinary and Genital Oncology Studies (12 papers) and Cancer Mechanisms and Therapy (10 papers). Sheldon L. Holder collaborates with scholars based in United States, Australia and Finland. Sheldon L. Holder's co-authors include Michelle M. Lilly, Marina Zemskova, Joseph J. Drabick, Monika Joshi, Matthew Kaag, Ming Yin, Harold A. Harvey, Simon Horenblas, Richard P. Meijer and Michael Glantz and has published in prestigious journals such as Journal of Biological Chemistry, Journal of Clinical Oncology and Blood.

In The Last Decade

Sheldon L. Holder

39 papers receiving 1.0k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer: A Systematic Review and Two-Step Meta-Analysis

2016 314 citations Ming Yin, Monika Joshi et al. The Oncologist profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Sheldon L. Holder United States	13	429	386	348	341	161	40	1.0k
M. Ravic United Kingdom	14	398 0.9×	222 0.6×	114 0.3×	299 0.9×	92 0.6×	36	973
Rahul Atul Parikh United States	17	333 0.8×	188 0.5×	35 0.1×	385 1.1×	251 1.6×	69	816
Sakkaraiappan Ramalingam United States	12	334 0.8×	125 0.3×	36 0.1×	376 1.1×	334 2.1×	30	909
Fraser Symmans United States	14	597 1.4×	112 0.3×	124 0.4×	596 1.7×	317 2.0×	21	1.2k
Patrick J. Hensley United States	15	216 0.5×	313 0.8×	38 0.1×	336 1.0×	249 1.5×	75	848
Mi Kwon Son South Korea	18	302 0.7×	65 0.2×	63 0.2×	418 1.2×	62 0.4×	41	830
Lingya Pan China	22	228 0.5×	193 0.5×	65 0.2×	494 1.4×	134 0.8×	108	1.4k
Wei‐Shone Chen Taiwan	20	680 1.6×	294 0.8×	206 0.6×	375 1.1×	197 1.2×	47	1.2k
Allyson L. Parr United States	12	711 1.7×	153 0.4×	250 0.7×	305 0.9×	297 1.8×	15	1.0k
Yu‐Li Su Taiwan	15	247 0.6×	218 0.6×	67 0.2×	147 0.4×	172 1.1×	75	637

Countries citing papers authored by Sheldon L. Holder

Since Specialization

Citations

This map shows the geographic impact of Sheldon L. Holder's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sheldon L. Holder with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sheldon L. Holder more than expected).

Fields of papers citing papers by Sheldon L. Holder

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sheldon L. Holder. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sheldon L. Holder. The network helps show where Sheldon L. Holder may publish in the future.

Co-authorship network of co-authors of Sheldon L. Holder

This figure shows the co-authorship network connecting the top 25 collaborators of Sheldon L. Holder. A scholar is included among the top collaborators of Sheldon L. Holder based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sheldon L. Holder. Sheldon L. Holder is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Slagle‐Webb, Becky, Chachrit Khunsriraksakul, Jingqin Luo, et al.. (2024). Analysis of anemia and iron supplementation among glioblastoma patients reveals sex-biased association between anemia and survival. Scientific Reports. 14(1). 2389–2389. 1 indexed citations

Lu, Shaolei, Vida Tajiknia, William MacDonald, et al.. (2024). Abstract 2954: Androgen deprivation therapy (ADT) and senescence-associated secretory phenotype (SASP) in vitro: Correlation with SASP in tumor specimens as well as in the serum of patients after ADT. Cancer Research. 84(6_Supplement). 2954–2954.

Joshi, Monika, Leonard Tuanquin, Junjia Zhu, et al.. (2023). Concurrent durvalumab and radiation therapy (DUART) followed by adjuvant durvalumab in patients with localized urothelial cancer of bladder: results from phase II study, BTCRC-GU15-023. Journal for ImmunoTherapy of Cancer. 11(2). e006551–e006551. 18 indexed citations

Souza, André De, Dragan Golijanin, Adam J. Olszewski, et al.. (2023). Abstract CT158: BrUOG360: A phase Ib/II study of copanlisib combined with rucaparib in patients with metastatic castration-resistant prostate cancer (mCRPC). Cancer Research. 83(8_Supplement). CT158–CT158. 1 indexed citations

Lehrer, Eric J., Daniel M. Trifiletti, Shankar Siva, et al.. (2022). A Patient-Level Data Meta-analysis of the Abscopal Effect. Advances in Radiation Oncology. 7(3). 100909–100909. 29 indexed citations

Joshi, Monika, Sheldon L. Holder, Junjia Zhu, et al.. (2021). Avelumab in Combination with Eribulin Mesylate in Metastatic Urothelial Carcinoma: BTCRC GU-051, a Phase 1b Study. European Urology Focus. 8(2). 483–490. 6 indexed citations

Yin, Ming, Petros Grivas, Qi-En Wang, et al.. (2020). Prognostic Value of DNA Damage Response Genomic Alterations in Relapsed/Advanced Urothelial Cancer. The Oncologist. 25(8). 680–688. 12 indexed citations

Joshi, Monika, Yousef Zakharia, M. Kaag, et al.. (2020). Concurrent Durvalumab And Radiation Therapy (DUART) followed by Adjuvant Durvalumab in Patients with Localized Urothelial Cancer of Bladder: BTCRC-GU15-023. International Journal of Radiation Oncology*Biology*Physics. 108(3). S29–S30. 1 indexed citations

Wang, Ming, Guangqing Chi, Sheldon L. Holder, et al.. (2019). Temporal and spatial trends and determinants of aggressive prostate cancer among Black and White men with prostate cancer. Cancer Causes & Control. 31(1). 63–71. 15 indexed citations

10.

Walter, Vonn, Jay D. Raman, Matthew Kaag, et al.. (2018). Mitotic activity in noninvasive papillary urothelial carcinoma: its value in predicting tumor recurrence and comparison with the contemporary 2-tier grading system. Human Pathology. 84. 275–282. 10 indexed citations

11.

Yin, Ming, Monika Joshi, Richard P. Meijer, et al.. (2016). Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer: A Systematic Review and Two-Step Meta-Analysis. The Oncologist. 21(6). 708–715. 314 indexed citations breakdown →

12.

Mackley, Heath B., Suhail M. Ali, Henry Wagner, et al.. (2016). Consolidation With Radiation or Concurrent Chemo-Radiation After Chemotherapy Results in Durable Complete Remissions of Isolated Nodal Recurrences of Urothelial Cancer: A Case Series and Review. Clinical Genitourinary Cancer. 14(4). e393–e399. 2 indexed citations

13.

Holder, Sheldon L., et al.. (2016). Current Immunotherapies for Renal Cell Carcinoma. Current Molecular Pharmacology. 9(3). 252–263. 2 indexed citations

14.

Yin, Ming, Wenge Wang, Jennifer Rosenberg, et al.. (2015). Targeted Therapy in Collecting Duct Carcinoma of the Kidney: A Case Report and Literature Review. Clinical Genitourinary Cancer. 14(2). e203–e206. 11 indexed citations

15.

Wang, Wenge, Sheldon L. Holder, Monika Joshi, et al.. (2015). Symptomatic Secondary Polycythemia Induced by Anti-VEGF Therapy for the Treatment of Metastatic Renal Cell Carcinoma: A Case Series and Review. Clinical Genitourinary Cancer. 13(6). e391–e395. 15 indexed citations

16.

Gatalica, Zoran, et al.. (2015). Therapeutic approach guided by genetic alteration: Use of MTOR inhibitor in renal medullary carcinoma with loss of PTEN expression. Cancer Biology & Therapy. 16(1). 28–33. 11 indexed citations

17.

Holder, Sheldon L. & Sarki A. Abdulkadir. (2014). PIM1 Kinase as a Target in Prostate Cancer: Roles in Tumorigenesis, Castration Resistance, and Docetaxel Resistance. Current Cancer Drug Targets. 14(2). 105–114. 38 indexed citations

18.

Holder, Sheldon L., Marina Zemskova, Chao Zhang, et al.. (2007). Characterization of a potent and selective small-molecule inhibitor of the PIM1 kinase. Molecular Cancer Therapeutics. 6(1). 163–172. 158 indexed citations

19.

Holder, Sheldon L., Michelle M. Lilly, & Milton L. Brown. (2007). Comparative molecular field analysis of flavonoid inhibitors of the PIM-1 kinase. Bioorganic & Medicinal Chemistry. 15(19). 6463–6473. 34 indexed citations

20.

Yan, Bin, Marina Zemskova, Sheldon L. Holder, et al.. (2003). The PIM-2 Kinase Phosphorylates BAD on Serine 112 and Reverses BAD-induced Cell Death. Journal of Biological Chemistry. 278(46). 45358–45367. 214 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact